# A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease

> **NCT01400503** · PHASE2 · COMPLETED · sponsor: **Janssen Research & Development, LLC** · enrollment: 60 (actual)

## Conditions studied

- Multicentric Castleman's Disease

## Interventions

- **DRUG:** Siltuximab

## Key facts

- **NCT ID:** NCT01400503
- **Lead sponsor:** Janssen Research & Development, LLC
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2011-04-01
- **Primary completion:** 2017-03-01
- **Final completion:** 2017-03-01
- **Target enrollment:** 60 (ACTUAL)
- **Last updated:** 2018-05-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01400503

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01400503, "A Study to Evaluate the Safety of Long-term Treatment With Siltuximab in Patients With Multicentric Castleman's Disease". Retrieved via AI Analytics 2026-06-01 from https://api.ai-analytics.org/clinical/NCT01400503. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*